Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials

Figures & data

Table 1 Baseline demographics and characteristics for patients with Acinetobacter infections: ME population

Characteristic	CAP			DFIs			HAP			cIAIs			RPs			cSSSI
	T	C	P	T	C	P	T	C	P	T	C	P	T	C	P	T	C	P
n	2	0		13	20		33	37		17	11		20	1		10	10
Age, years						0.810			0.498			0.003			0.473			0.655
Mean (SE)	36.0 (16.0)			55.6 (3.6)	56.5 (1.8)		49.6 (3.6)	52.8 (3.3)		53.7 (4.2)	32.7 (4.8)		49.8 (4.5)	65.0 (0)		54.9 (6.8)	58.8 (5.3)
Median (range)	36.0 (20.0–52.0)			55.0 (27.0–70.0)	56.5 (35.0–74.0)		51.0 (18.0–81.0)	53.0 (19.0–88.0)		56.0 (22.0–79.0)	25.0 (19.0–68.0)		43.5 (22.0–86.0)	65.0 (65.0–65.0)		54.5 (21.0–88.0)	58.0 (25.0–80.0)
Sex, n (%)						0.338			0.111			0.390			0.105			0.329
Female	0			2 (15.4)	6 (30.0)		6 (18.2)	13 (35.1)		9 (52.9)	4 (36.4)		5 (25.0)	1 (100)		2 (20.0)	4 (40.0)
Male	2 (100)			11 (84.6)	14 (70.0)		27 (81.8)	24 (64.9)		8 (47.1)	7 (63.6)		15 (75.0)	0		8 (80.0)	6 (60.0)
Ethnicity, n (%)						0.515			0.802			0.138			0.74			0.261
Black	0			0	1 (5.0)		0	1 (2.7)		0	0		0	0		2 (20.0)	0
Han	0			0	0		0	0		1 (5.9)	2 (18.2)		0	0		0	0
Hispanic	0			0	0		8 (24.2)	6 (16.2)		2 (11.8)	1 (9.1)		2 (10.0)	0		0	1 (10.0)
Oriental (Asian)	0			0	2 (10.0)		11 (33.3)	12 (32.4)		0	2 (18.2)		0	0		0	1 (10.0)
White	2 (100)			10 (76.9)	14 (70.0)		13 (39.4)	17 (45.9)		14 (82.4)	5 (45.5)		18 (90.0)	1 (100)		8 (80.0)	8 (80.0)
Other	0			3 (23.1)	3 (15.0)		1 (3.0)	1 (2.7)		0	1 (9.1)		0	0		0	0
Underlying comorbidities
Diabetes mellitus, n (%)	0			13 (100)	20 (100)		6 (18.2)	5 (13.5)	0.592	1 (5.9)	1 (9.1)	0.747	1 (5.0)	1 (100)	0.002	3 (30.0)	2 (20.0)	0.606
COPD, n (%)	0			0	0		5 (15.2)	4 (10.8)	0.588	0	0		1 (5.0)	0	0.819	1 (10.0)	1 (10.0)	1.000
Disease severity
APACHE II,a mean (SE)	NA			NA	NA		12.52 (1.04)	12.59 (0.93)	0.954	6.00 (1.15)	6.64 (1.40)	0.729	9.15 (1.38)	16.00 (0)	0.292	NA	NA
ICU, n (%)	0			0	0		2 (6.1)	0	0.129	4 (23.5)	2 (18.2)	0.736	0	0		0	1 (10.0)	0.305
Mono- vs polymicrobial infection, n (%)									0.874			0.747			0.619
Mono-	0			0	0		11 (33.3)	13 (35.1)		1 (5.9)	1 (9.1)		4 (20.0)	0		0	0
Poly-	2 (100)			13 (100)	20 (100)		22 (66.7)	24 (64.9)		16 (94.1)	10 (90.9)		16 (80.0)	1 (100)		10 (100)	10 (100)
Bacteremia, n (%)	1 (50.0)			1 (7.7)	1 (5.0)	0.751	3 (9.1)	7 (18.9)	0.241	2 (11.8)	1 (9.1)	0.823	2 (10.0)	0	0.74	0	0
Prior antibiotic failure, n (%)	0			0	0		14 (42.4)	10 (27)	0.175	2 (11.8)	1 (9.1)	0.823	20 (100)	1 (100)		1 (10.0)	2 (20.0)	0.531
Resistance to antibiotic classes/antibiotics, n (%)
Tigecycline	0			0	0		1 (3.0)	0	0.286	0	0		0	0		0	0
Carbapenems (imipenem)	0			0	0		5 (15.2)	5 (13.5)	0.845	1 (5.9)	0	0.413	9 (45.0)	0	0.375	0	0
Aminoglycosides	0			0	0		23 (69.7)	31 (83.8)	0.161	4 (23.5)	2 (18.2)	0.736	8 (40.0)	0	0.421	2 (20.0)	2 (20.0)	1.000
Quinolones	0			8 (61.5)	8 (40.0)	0.226	20 (60.6)	26 (70.3)	0.395	3 (17.6)	2 (18.2)	0.971	13 (65.0)	0	0.191	1 (10.0)	1 (10.0)	1.000
Cephalosporin	0			10 (76.9)	9 (45.0)	0.07	18 (54.5)	29 (78.4)	0.034	5 (29.4)	4 (36.4)	0.700	15 (75.0)	0	0.105	1 (10.0)	3 (30.0)	0.264
β-Lactams	0			10 (76.9)	12 (60.0)	0.314	0	0		7 (41.2)	3 (27.3)	0.453	0	0		2 (20.0)	2 (20.0)	1.000
MDR	0			8 (61.5)	7 (35.0)	0.135	11 (33.3)	25 (67.6)	0.004	4 (23.5)	2 (18.2)	0.736	7 (35.0)	0	0.469	1 (10.0)	1 (10.0)	1.000
Mechanical ventilation,bn (%)	NA			NA	NA		25 (75.8)	25 (67.6)	0.449	NA	NA		NA	NA		NA	NA
Adjunctive therapy for HAP,bn (%)	NA			NA	NA		27 (81.8)	30 (81.1)	0.937	NA	NA		NA	NA		NA	NA

Notes:

a Some studies did not have records for this variable;

b NA for all indications that are not HAP. P-values for comparisons between treatment groups.

Abbreviations: C, comparator group; CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia; ICU, intensive care unit; MDR, multidrug-resistant; ME, microbiologically evaluable; NA, not applicable; RPs, resistant pathogens; T, tigecycline group.

Figure 1 Clinical response in patients with Acinetobacter infections in the ME population.

Notes: (A) Overall population; (B) by presence of MDR Acinetobacter; (C) by presence of bacteremia; (D) by prior antibiotic failure.

Abbreviations: CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant; ME, microbiologically evaluable; RPs, resistant pathogens; ROC, rate of cure.

Table 2 Clinical and microbiological responses to tigecycline at TOC visit for patients with Acinetobacter infection in ME population by MIC value

Infection	MIC (μg/mL)	Patients by MIC, n	Clinical response		Microbiological response
			Cure, n (%)		Eradication, n (%)
CAP
	0.12	2	1	(50.0)	1	(50.0)
DFIs
	0.06	3	2	(66.7)	1	(33.3)
	0.12	2	2	(100)	1	(50.0)
	0.5	3	3	(100)	2	(66.7)
	1	5	3	(60.0)	3	(60.0)
HAP
	0.12	1	1	(100)	0
	0.25	3	1	(33.3)	1	(33.3)
	0.5	4	4	(100)	4	(100)
	1	12	8	(66.7)	7	(58.3)
	2	8	5	(62.5)	5	(62.5)
	4	4	3	(75.0)	3	(75.0)
	8	1	0		0
cIAIs
	0.06	1	1	(100)	1	(100)
	0.12	5	4	(80.0)	4	(80.0)
	0.25	4	3	(75.0)	3	(75.0)
	0.5	1	1	(100)	1	(100)
	1	4	4	(100)	4	(100)
	2	2	2	(100)	2	(100)
RPs
	0.25	1	1	(100)	1	(100)
	0.5	5	5	(100)	5	(100)
	1	7	6	(85.7)	5	(71.4)
	2	4	2	(50.0)	0
	4	3	2	(66.7)	2	(66.7)
cSSSIs
	0.12	3	2	(66.7)	2	(66.7)
	0.25	3	2	(66.7)	2	(66.7)
	0.5	2	2	(100)	2	(100)
	1	2	1	(50.0)	1	(50.0)

Notes: Percentages are for proportions of patients with positive response in each MIC category. For patients with DFIs, tigecycline dosing was 150 mg once daily; for patients with other types of infection, tigecycline was administered 100 mg initially once, then 50 mg every 12 hours. For patients with HAP, concomitant medications were administered.

Abbreviations: CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia; ME, microbiologically evaluable; MIC, minimum inhibitory concentration; RPs, resistant pathogens; TOC, test of cure.

Table 3 Discontinuations and deaths in patients with Acinetobacter: MITT population

	Total, n=274	Tigecycline, n=154	Comparator, n=120
Discontinuations from study drug, n (%)
Overall	11 (4.0)	5 (3.2)	6 (5.0)
Adverse events	4 (1.5)	2 (1.3)	2 (1.7)
Patient request unrelated to study	1 (0.4)	1 (0.6)	0
Unsatisfactory response – efficacy	4 (1.5)	1 (0.6)	3 (2.5)
Other	2 (0.7)	1 (0.6)	1 (0.8)
Discontinuations from study, n (%)
Overall	5 (1.8)	2 (1.3)	3 (2.5)
Lost to follow-up	1 (0.4)	0	1 (0.8)
Unsatisfactory response – efficacy	1 (0.4)	0	1 (0.8)
Other	3 (1.1)	2 (1.3)	1 (0.8)
Deaths in MITT population, n/N (%)
Overall	28/274 (10.2)	17/154 (11.0)	11/120 (9.2)
CAP	0/2	0/2	0/0
DFIs	0/45	0/19	0/26
HAP	20/121 (16.5)	9/57 (15.8)	11/64 (17.2)
cIAIs	1/35 (2.9)	1/21 (4.8)	0/14
RPs	6/40 (15.0)	6/39 (15.4)	0/1
cSSSIs	1/31 (3.2)	1/16 (6.3)	0/15
Deaths among MDR patients in MITT population, n/N (%)
Overall	10/126 (7.9)	6/65 (9.2)	4/61 (6.6)

Abbreviations: CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant; MITT, modified intent-to-treat; n, number of patients or deaths in a specific group; N, total number of patients in a specific group; RPs, resistant pathogens.

Table S1 List of pathogens other than Acinetobacter spp. isolated from patients

	Tigecycline	%	Comparator	%
CAP	n=2		n=0
Gram-negative pathogens	2	100.0	0	0.0
Haemophilus influenzae	2	100.0	0	0.0
Haemophilus parainfluenzae	1	50.0	0	0.0
Gram-positive pathogens	2	100.0	0	0.0
Aerococcus viridans	1	50.0	0	0.0
Kocuria rosea	1	50.0	0	0.0
Staphylococcus aureus	1	50.0	0	0.0
Streptococcus equisimilis	1	50.0	0	0.0
Streptococcus pneumoniae	2	100.0	0	0.0
DFIs	n=14		n=21
Anaerobes	2	14.3	1	4.8
Bacteroides fragilis	1	7.1	0	0.0
Bacteroides fragilis group	1	7.1	0	0.0
Finegoldia magna	0	0.0	1	4.8
Prevotella bivia	1	7.1	0	0.0
Veillonella spp.	1	7.1	0	0.0
Gram-negative pathogens	7	50.0	9	42.9
Citrobacter freundii complex	1	7.1	1	4.8
Enterobacter cloacae	1	7.1	4	19.0
Enterobacter sakazakii	0	0.0	1	4.8
Escherichia coli	0	0.0	3	14.3
Klebsiella oxytoca	1	7.1	0	0.0
Klebsiella pneumoniae	2	14.3	2	9.5
Leclercia adecarboxylata	0	0	1	4.8
Morganella morganii	1	7.1	0	0.0
Nonfermentative Gram-negative rods	1	7.1	0	0.0
Proteus mirabilis	1	7.1	3	14.3
Proteus vulgaris group	0	0.0	1	4.8
Pseudomonas mendocina	1	7.1	0	0.0
Gram-positive anaerobes	1	7.1	2	9.5
Clostridium perfringens	0	0.0	1	4.8
Peptostreptococcus tetradius	1	7.1	0	0.0
Propionibacterium acnes	0	0.0	1	4.8
Gram-positive pathogens	10	71.4	21	100.0
Brevibacterium spp.	0	0.0	1	4.8
Corynebacterium macginleyi	1	7.1	0	0.0
Corynebacterium spp.	0	0.0	1	4.8
Corynebacterium striatum	0	0.0	1	4.8
Enterococcus casseliflavus	0	0.0	1	4.8
Enterococcus faecalis	3	21.4	7	33.3
Enterococcus faecium	0	0.0	1	4.8
Enterococcus gallinarum	0	0.0	1	4.8
Staphylococcus aureus	9	64.3	11	52.4
Staphylococcus epidermidis	0	0.0	1	4.8
Staphylococcus warneri	0	0.0	1	4.8
Staphylococcus xylosus	0	0.0	1	4.8
Streptococcus agalactiae	3	21.4	2	9.5
Streptococcus canis	1	7.1	0	0.0
Streptococcus dysgalactiae	0	0.0	1	4.8
Streptococcus pyogenes	0	0.0	1	4.8
Vagococcus spp.	1	7.1	0	0.0
HAP	n=39		n=40
Fungus	0	0.0	2	5.0
Candida albicans	0	0.0	2	5.0
Gram-negative pathogens	24	61.5	30	75.0
Chryseobacterium indologenes	1	2.6	0	0.0
Citrobacter freundii complex	1	2.6	1	2.5
Enterobacter amnigenus	1	2.6	0	0.0
Enterobacter cloacae	0	0.0	5	12.5
Escherichia coli	1	2.6	4	10.0
Haemophilus influenzae	2	5.1	3	7.5
Klebsiella oxytoca	0	0.0	1	2.5
Klebsiella pneumoniae	5	12.8	11	27.5
Klebsiella terrigena	1	2.6	0	0.0
Moraxella catarrhalis	0	0.0	1	2.5
Morganella morganii	1	2.6	0	0.0
Neisseria sicca	0	0.0	1	2.5
Proteus mirabilis	2	5.1	0	0.0
Providencia stuartii	1	2.6	0	0.0
Pseudomonas aeruginosa	9	23.1	10	25.0
Salmonella spp.	0	0.0	1	2.5
Serratia marcescens	0	0.0	1	2.5
Stenotrophomonas maltophilia	2	5.1	2	5.0
Gram-positive pathogens	25	64.1	23	57.5
Bacillus spp. not anthracis	0	0.0	2	5.0
Enterococcus durans	0	0.0	1	2.5
Enterococcus faecalis	3	7.7	1	2.5
Enterococcus faecium	2	5.1	0	0.0
Staphylococcus aureus	22	56.4	16	40.0
Staphylococcus epidermidis	2	5.1	0	0.0
Staphylococcus haemolyticus	1	2.6	4	10.0
Staphylococcus hominis	0	0.0	1	2.5
Streptococcus constellatus	1	2.6	0	0.0
Streptococcus mitis	0	0.0	1	2.5
Streptococcus oralis	0	0.0	1	2.5
Streptococcus pneumoniae	2	5.1	0	0.0
cIAIs	n=19		n=11
Anaerobes	5	26.3	4	36.4
Bacteroides fragilis	3	15.8	0	0.0
Bacteroides ovatus	2	10.5	0	0.0
Bacteroides stercoris	0	0.0	1	9.1
Bacteroides thetaiotaomicron	1	5.3	1	9.1
Bacteroides uniformis	0	0.0	2	18.2
Prevotella melaninogenica	0	0.0	1	9.1
Gram-negative pathogens	15	78.9	8	72.7
Citrobacter freundii complex	2	10.5	0	0.0
Enterobacter cancerogenus	0	0.0	1	9.1
Enterobacter cloacae	3	15.8	0	0.0
Escherichia coli	9	47.4	6	54.5
Klebsiella pneumoniae	3	15.8	0	0.0
Morganella morganii	0	0.0	1	9.1
Neisseria gonorrhoeae	1	5.3	0	0.0
Proteus mirabilis	2	10.5	0	0.0
Pseudomonas aeruginosa	2	10.5	2	18.2
Gram-positive anaerobes	3	15.8	3	27.3
Bifidobacterium angulatum	1	5.3	0	0.0
Clostridium sporogenes	1	5.3	0	0.0
Peptoniphilus asaccharolyticus	0	0.0	1	9.1
Propionibacterium acnes	1	5.3	1	9.1
Propionibacterium granulosum	0	0.0	1	9.1
Gram-positive pathogens	12	63.2	6	54.5
Actinomyces israelii	0	0.0	1	9.1
Actinomyces odontolyticus	1	5.3	0	0.0
Aerococcus viridans	2	10.5	0	0.0
Enterococcus avium	1	5.3	0	0.0
Enterococcus faecalis	2	10.5	2	18.2
Enterococcus gallinarum	1	5.3	0	0.0
Lactobacillus spp.	1	5.3	0	0.0
Staphylococcus aureus	4	21.1	1	9.1
Staphylococcus auricularis	0	0.0	1	9.1
Staphylococcus capitis	0	0.0	1	9.1
Staphylococcus epidermidis	1	5.3	0	0.0
Streptococcus anginosus	2	10.5	2	18.2
Resistant pathogens	n=28		n=1
Fungus	1	3.6	0	0.0
Candida parapsilosis	1	3.6	0	0.0
Gram-negative pathogens	14	50.0	0	0.0
Enterobacter cloacae	1	3.6	0	0.0
Escherichia coli	6	21.4	0	0.0
Klebsiella pneumoniae	2	7.1	0	0.0
Morganella morganii	1	3.6	0	0.0
Proteus mirabilis	1	3.6	0	0.0
Proteus vulgaris	1	3.6	0	0.0
Pseudomonas aeruginosa	3	10.7	0	0.0
Stenotrophomonas maltophilia	1	3.6	0	0.0
Gram-positive pathogens	19	67.9	1	100.0
Enterococcus faecalis	6	21.4	0	0.0
Enterococcus faecium	0	0.0	1	100.0
Lactobacillus casei	1	3.6	0	0.0
Staphylococcus aureus	15	53.6	0	0.0
Streptococcus pyogenes	1	3.6	0	0.0
cSSSIs	n=15		n=13
Gram-negative pathogens	7	46.7	6	46.2
Citrobacter freundii	0	0.0	1	7.7
Enterobacter cloacae	1	6.7	0	0.0
Escherichia coli	2	13.3	3	23.1
Klebsiella oxytoca	0	0.0	1	7.7
Klebsiella pneumoniae	1	6.7	0	0.0
Leclercia adecarboxylata	1	6.7	0	0.0
Morganella morganii	1	6.7	0	0.0
Proteus mirabilis	0	0.0	1	7.7
Pseudomonas aeruginosa	2	13.3	0	0.0
Serratia marcescens	1	6.7	0	0.0
Stenotrophomonas maltophilia	1	6.7	1	7.7
Gram-positive pathogens	13	86.7	13	100.0
Aerococcus viridans	1	6.7	0	0.0
Brevibacterium spp.	0	0.0	1	7.7
Corynebacterium pseudodiphtheriticum	0	0.0	1	7.7
Corynebacterium striatum	1	6.7	0	0.0
Enterococcus faecalis	3	20.0	2	15.4
Staphylococcus aureus	5	33.3	7	53.8
Staphylococcus capitis	1	6.7	0	0.0
Staphylococcus epidermidis	1	6.7	0	0.0
Staphylococcus haemolyticus	1	6.7	0	0.0
Staphylococcus hominis	0	0.0	1	7.7
Staphylococcus kloosii	1	6.7	0	0.0
Staphylococcus lugdunensis	0	0.0	1	7.7
Staphylococcus schleiferi	0	0.0	1	7.7
Staphylococcus sciuri	0	0.0	1	7.7
Streptococcus agalactiae	0	0.0	2	15.4
Streptococcus anginosus	1	6.7	1	7.7
Streptococcus bovis	0	0.0	1	7.7
Streptococcus constellatus	0	0.0	1	7.7
Streptococcus dysgalactiae	0	0.0	2	15.4
Streptococcus equisimilis	1	6.7	0	0.0
Streptococcus mitis	1	6.7	0	0.0
Streptococcus oralis	2	13.3	1	7.7
Streptococcus pyogenes	1	6.7	0	0.0
Streptococcus sanguinis	0	0.0	1	7.7

Abbreviations: CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia.

Table S2 Clinical response (rate of cure) in patients with Acinetobacter infections in the ME population

	CAP, n/N (%) 95% CI	DFIs, n/N (%) 95% CI	HAP, n/N (%) 95% CI	cIAIs, n/N (%) 95% CI	RPs, n/N (%) 95% CI	cSSSIs, n/N (%) 95% CI
Overall
Tigecycline	1/2 (50.0) 12.5–87.5	10/13 (76.9) 57.7–94.2	22/33 (66.7) 50.0–75.0	15/17 (88.2) 66.2–97.1	16/20 (80.0) 60.0–95.0	7/10 (70.0) 17.5–92.5
Comparator		17/20 (85.0) 63.8–96.3	31/37 (83.8) 62.8–95.9	11/11 (100.0) 75.0–100.0	1/1 (100.0) 25.0–100.0	9/10 (90.0) 67.5–97.5
MDR Acinetobacter
Yes: tigecycline		7/8 (87.5) 65.6–96.9	8/11 (72.7) 54.5–93.2	4/4 (100.0) 25.0–100.0	6/7 (85.7) 21.4–96.4	0/1 (0.0) 0.0–75.0
Comparator		7/7 (100.0) 75.0–100.0	22/25 (88.0) 66.0–97.0	2/2 (100.0) 25.0–100.0		0/1 (0.0) 0.0–75.0
No: tigecycline	1/2 (50.0) 12.5–87.5	3/5 (60.0) 15.0–90.0	14/22 (63.6) 47.7–90.9	11/13 (84.6) 63.5–96.2	10/13 (76.9) 57.7–94.2	7/9 (77.8) 58.3–94.4
Comparator		10/13 (76.9) 57.7–94.2	9/12 (75.0) 56.3–93.8	9/9 (100.0) 75.0–100.0	1/1 (100.0) 25.0–100.0	9/9 (100.0) 75.0–100.0
Bacteremia
Yes: tigecycline	0/1 (0.0) 0.0–75.0	1/1 (100.0) 25.0–100.0	1/3 (33.3) 8.3–83.3	1/2 (50.0) 12.5–87.5	1/2 (50.0) 12.5–87.5
Comparator		1/1 (100.0) 25.0–100.0	5/7 (71.4) 17.9–92.9	1/1 (100.0) 25.0–100.0
No: tigecycline	1/1 (100.0) 25.0–100.0	9/12 (75.0) 56.3–93.8	21/30 (70.0) 52.5–92.5	14/15 (93.3) 70.0–98.3	15/18 (83.3) 62.5–95.8	7/10 (70.0) 17.5–92.5
Comparator		16/19 (84.2) 63.2–96.1	26/30 (86.7) 65.0–96.7	10/10 (100.0) 75.0–100.0	1/1 (100.0) 25.0–100.0	9/10 (90.0) 67.5–97.5
Prior antibiotic failure
Yes: tigecycline			8/14 (57.1) 42.9–89.3	2/2 (100.0) 25.0–100.0	16/20 (80.0) 60.0–95.0	1/1 (100.0) 25.0–100.0
Comparator			6/10 (60.0) 15.0–90.0	1/1 (100.0) 25.0–100.0	1/1 (100.0) 25.0–100.0	2/2 (100.0) 25.0–100.0
No: tigecycline	1/2 (50.0) 12.5–87.5	10/13 (76.9) 57.7–94.2	14/19 (73.7) 55.3–93.4	13/15 (86.7) 65.0–96.7		6/9 (66.7) 16.7–91.7
Comparator		17/20 (85.0) 63.8–96.3	25/27 (92.6) 69.4–98.1	10/10 (100.0) 75.0–100.0		7/8 (87.5) 65.6–96.9

Note: 95% CI for each treatment group calculated using the Clopper–Pearson method.

Abbreviations: CAP, community-acquired pneumonia; cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin-structure infections; DFIs, diabetic foot infections; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant; ME, microbiologically evaluable; MIC, minimum inhibitory concentration; n, number of patients with positive clinical response (ie, cure); N, total number of patients in the specific category; RPs, resistant pathogens; TOC, test of cure.